FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to antibodies and their antigen-binding fragments designed to bind the transforming growth factor-β (TGFβ1, TGFβ2 and TGFβ3), which can be used in medicine. Antibodies are obtained, along with a nucleic acid encoding said antibodies, an expression vector comprising said nucleic acid and a host cell for producing said antibody or antigen-binding fragment, and a pharmaceutical composition for treating a patient in need of inhibiting one or more of TGFβ1, TGFβ2 and TGFβ3.
EFFECT: invention makes it possible to obtain antibodies to TGFβ1, TGFβ2 and TGFβ3 with improved affinity, which increases the affinity of their binding and, therefore, improves the efficacy of treating diseases in which one or more of TGFβ1, TGFβ2 and TGFβ3.
22 cl, 5 dwg, 9 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SCFV-FC DIMERS WHICH BIND TO THE TRANSFORMING GROWTH FACTOR β1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | 2016 |
|
RU2733286C2 |
| MODIFIED IGG ANTIBODIES WHICH BIND TO A TRANSFORMING GROWTH FACTOR BETA-1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | 2016 |
|
RU2728858C2 |
| ANTIGEN ASSOCIATED WITH RHEUMATOID ARTHRITIS | 2013 |
|
RU2649368C2 |
| RECOMBINANT ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF), OBTAINED BY VARIABLE REGION MUTAGENESIS | 2011 |
|
RU2557309C2 |
| ANTIGENS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE | 2012 |
|
RU2612878C2 |
| ANTI-LRP6 ANTIBODIES | 2011 |
|
RU2587625C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2016 |
|
RU2648152C2 |
| POLYPEPTIDES FOR BONDING WITH "RECEPTOR OF ADVANCED GLYCATION ENDPRODUCTS", THEIR COMPOSITIONS AND METHODS, WHICH THEY TAKE PART IN | 2010 |
|
RU2558301C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2011 |
|
RU2774414C2 |
| STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF | 2009 |
|
RU2588467C2 |
